Navidea Biopharmaceuticals Inc (NAVBQ)

[kookiekook]

Navidea apparent low revenues and "high" cash burn rate are due to:

Lymphoseek approval for a limited sector of its potential users. They are seeking to expand the usage as evidence by their recent submission to the FDA.

They also had essentially no sales force when first approved.

NEW Drugs: Navidea has several drugs in phase II/III trials. These trials take large sums of money and time with little or no guarantee of success.